They have seen a surge in industry interest particularly following approvals for Novartis drugs Lutathera and last year Pluvicto. The drugs are tricky to make and even tougher to produce at scale. Though sales of the first radiopharmaceuticals approved were modest, Pluvicto and Lutathera are proving more successful